Teva Paid 0.3% Local Tax Rate in 2012

Biggest reason for paying record low taxes is that the company does not pay Israel on profits from its flagship branded drug Copaxone for treating multiple sclerosis.

Teva Pharmaceutical Industries paid a record low in Israeli taxes in 2012, amounting to just $5 million, or 0.3% of its $1.6 billion in earnings in the country, according to its annual financial statements.